Epoch (epoetin beta biosimilar) / Roche - LARVOL DELTA

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial. (PubMed, Lancet Haematol) - P2/3 | "The addition of venetoclax to DA-EPOCH-R resulted in excess mortality, prompting early study closure. Robust accrual shows that prospective multicentre trials are feasible in double-hit lymphoma, and the outcomes in the DA-EPOCH-R group serve as a benchmark for future studies."

Clinical • Journal • P2/3 data • B Cell Lymphoma • Cardiovascular • Febrile Neutropenia • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pulmonary Disease • Septic Shock • BCL6 • MYC

Chronic Lymphocytic Leukemia With Plasmablastic Transformation in a Patient Treated With Acalabrutinib: A Case Report (SOHO 2026) - "Case Presentation: We report a 76-year-old man with CLL (del [13q], unmutated immunoglobulin heavy variable [IGHV], Rai stage 4) who was initially treated with ibrutinib, yet discontinued due to pericarditis and hemorrhagic effusion, then switched to acalabrutinib with stable disease for 3 years...Planned EPOCH (etoposide, prednisone, Oncovin [vincristine], and cyclophosphamide)-bortezomib chemotherapy was precluded by hemodynamic instability... Plasmablastic transformation in CLL, even in patients receiving effective BTKi therapy, is associated with a highly aggressive clinical course and a poor prognosis. This case emphasizes the importance of maintaining a high index of suspicion when patients on BTKis present new systemic symptoms or rapidly progressive, bulky lymphadenopathy. The case also highlights the significant therapeutic challenges and limited treatment options once transformation occurs."

Case report • Clinical • IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • CD20 • CD38 • CD5 • FCER2 • IGH • NCAM1 • SDC1

The Digital Twin Synthesis: Generating Synthetic Control Arms via Wasserstein Generative Adversarial Networks for Menin Inhibitors in Genetically Defined Acute Myeloid Leukemia (SOHO 2026) - "We constructed a historical cohort (N = 800) from FLAGIDA plus venetoclax salvage data and simulated a menin inhibitor trial cohort (N = 60) reflecting AUGMENT-101 and KOMET trial characteristics... WGAN-GP methodology addresses ESS collapse limitations in small single-arm menin inhibitor trials by generating demographically conditioned synthetic controls. Despite substantial baseline covariate imbalances reflected in Kolmogorov-Smirnov statistics, the adjusted survival comparison demonstrated no statistically significant difference between menin inhibitors and intensive salvage in genetically defined AML populations. This digital twin approach warrants validation in prospective comparative effectiveness studies and regulatory decision-making contexts for targeted therapies in molecularly stratified hematologic malignancies."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • KMT2A • NPM1

Diffusing the Double-Hit: A Tabular Diffusion Meta-Analysis Generating Counterfactual Survival Trajectories for MYC/BCL2 Double-Hit Lymphoma (SOHO 2026) - "Clinicians must choose between escalation to intensive dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab (DA-EPOCH-R) or early cellular therapy on the basis of only small, heterogeneous retrospective cohorts (typically 20–50 patients)... TabDDPM overcomes the fundamental limitations of propensity-scorematching and traditional meta-analysis by synthesizing rather than discarding non-overlapping patients, delivering the first statistically powered, bias-adjusted evidence synthesis for frontline therapy in DHL. This generative causal framework pioneers "what-if" oncology and provides clinicians with patient-specific counterfactual survival forecasts to guide personalized intensification while highlighting the perils of unadjusted observational data."

IO biomarker • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • High-grade B-cell lymphoma • Lymphoma • Oncology • BCL2 • MYC

Epstein-Barr Virus–Positive Sinonasal Plasma Cell Neoplasms: A Case Series With Favorable Outcomes in Older Men (SOHO 2026) - "These neoplasms in these cases showed less-aggressive clinical behavior than is typically seen in PBL, suggesting that this sinonasal tract disease in older men might represent a distinct subset of EBV-positive PCNs. This clinicopathologic profile could be more consistent with EBV-positive plasmacytoma, and better understanding of this profile could guide therapeutic management for future cases. CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; DA-EPOCH: dose-adjusted etoposide, prednisone, Oncovin (vincristine), cyclophosphamide, and hydroxydaunorubicin; EBER: Epstein-Barr virus–encoded small RNAs; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone."

Clinical • CNS Tumor • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology • Plasmacytoma • SDC1

TopoAdapter: a plug-and-play multi-hop topology adapter for MI-EEG decoding. (PubMed, J Neurosci Methods) - "TopoAdapter provides an explicit, ultra-lightweight spatial prior for motor EEG decoding. Positive mean changes on two motor-imagery datasets, one executed-movement dataset, and seven heterogeneous BCI IV-2a backbones support portability and a favorable cost-benefit profile, while effect magnitude remains dataset- and subject-dependent."

Journal • CNS Disorders

A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics (ASH 2024) - "For > 90% of pts, the RDI was ≥90% for all individual components except vincristine (78%). There were 2 dose interruptions of doxorubicin (AMI [n=1], and poor performance status [n=1]), and 5 interruptions of glofit, (infection [n=3], hepatotoxicity [n=1], and rash [n=1])...With these regimens, PMR at EOI does not necessarily represent treatment failure, and cfDNA may be useful to further investigate outcomes in this setting. CRR and preliminary PFS is promising compared to historical outcomes in pts with HR LBCL."

Clinical • FDG PET • P2 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Cardiomyopathy • Cardiovascular • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hepatology • Indolent Lymphoma • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6

Decreasing the Dose of Consolidation Radiation Therapy in DLBCL/HGBL: A Phase II Trial by the International Lymphoma Radiation Oncology Group (ASTRO 2025) - "ChI primarily consisted of R-CHOP (n=198, 82%) or R-EPOCH (n=19, 8%)... Results of this phase II study demonstrate high rates of local control with a lower dose of consolidation RT in a diverse population of patients with DLBCL/HGBL achieving a metabolic CR by post- ChI PET-CT. While guidelines currently recommend 30 Gy, this could be reduced to 20 Gy if high rates of local control are maintained with longer follow-up. A reduction in RT dose will decrease both acute and long-term toxicity."

P2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Oncology

Rising Trends and Persistent Regional Disparities in Non-Alcoholic/MASLD-Related Cirrhosis Incidence and Disability-Adjusted Life Years in the United States and Europe, 1990â2023: A Global Burden of Disease Study (ACG 2026) - "The United States demonstrated the steepest sustained ASIR rise (EAPC +0.59%, 95% CI 0.56â0.63), reaching 394.2 (95% UI 315.1â482.1) per 100,000 in 2023 â a 16.2% increase from 1990 â with joinpoint analysis identifying an inflection in 2013 (APCâ +0.58% â APCâ +0.24%). DALY rates in the US rose even faster (EAPC +1.07%, 95% CI 0.81â1.33), reaching 58.1 (34.4â89.8) per 100,000, reflecting a widening chronicity gap. Eastern Europe carried the highest absolute DALY burden (111.1 [63.9â177.6] per 100,000 in 2023), with an alarming EAPC of +1.74% (95% CI 1.28â2.21) â an 80.4% DALY increase since 1990 â driven by a 2005 joinpoint breakpoint."

Clinical • HEOR • Fibrosis • Genetic Disorders • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Novel Coronavirus Disease • Obesity

Personalized adaptive virtual reality experience driven by electroencephalography-based pain recognition. (PubMed, PLoS One) - "This system offers a scalable, drug-free alternative for pain management applicable in clinical and rehabilitation settings. The modular design facilitates future extensions, including emotional state tracking, haptic feedback, and reinforcement learning-based personalization."

Journal • CNS Disorders • Pain

Cross-species brain-wide mapping reveals convergent mesocorticolimbic engagement by nucleus accumbens deep brain stimulation. (PubMed, Mol Psychiatry) - "Simultaneous intracranial electrophysiology recordings from the human NAc and brief stimulation epochs of analogous mesocorticolimbic nodes revealed patterns of connectivity between these regions and the NAc. Altogether, these results link brain-wide network mapping in mice with a hypothesis-driven test of human NAc connectivity, consistent with a coordinated mesocorticolimbic network that may be relevant to the mechanisms of NAc DBS."

Journal • CNS Disorders • Mental Retardation • Psychiatry

Differential glutamate modulation in the anterior mid-cingulate cortex of healthy adults during inhibitory motor control utilizing a novel interleaved baseline control condition: a ¹H fMRS study. (PubMed, Brain Struct Funct) - "A task order effect showed higher glutamate among participants who (randomly) completed the non-selective task run first. Non-selective motor responding drove increased aMCC glutamate relative to periods without motor responding whereas the effect was absent for the selective responding mode. Our findings suggest that generalized motor control processes increased aMCC excitatory neuromodulation drive, whereas the additional engagement of inhibitory control processes did not change the excitatory neuromodulation drive."

Journal

Transcutaneous auricular vagus nerve stimulation and emotional responding in borderline personality disorder: a randomized single-blind, sham-controlled study. (PubMed, Borderline Personal Disord Emot Dysregul) - P=N/A | "In this preliminary single-session randomized sham-controlled study, active taVNS was associated with lower self-reported negative affect during a mood-induction paradigm in women with BPD. This subjective effect was not accompanied by treatment-related effects on heart rate, lnRMSSD, or phasic EDA response frequency, while the tonic skin conductance interaction should be interpreted cautiously as exploratory. These findings support further investigation of taVNS as a mechanistic probe of acute affective responding in BPD."

Journal • Borderline Personality Disorder • CNS Disorders • Mood Disorders • Personality Disorder • Psychiatry

Comparative Seizure Outcomes of Vagus Nerve Stimulation, Deep Brain Stimulation, and Their Combination in Lennox-Gastaut Syndrome. (PubMed, Ann Neurol) - "VNS and DBS provide comparable seizure reduction in LGS over a 2-year follow-up period. DBS + VNS was associated with further improvements in seizure reduction in this small, retrospective dataset. This possibility warrants further investigation. ANN NEUROL 2026."

Journal • CNS Disorders • Epilepsy

Anatomically constrained deep learning for clinical-grade volumetric pancreatic cancer segmentation: development, validation, and architectural benchmarking. (PubMed, NPJ Precis Oncol) - "On a difficulty-enriched subset (n = 50), Model-BB achieved DSC 0.71 against a STAPLE-derived consensus, exceeding individual reader-pair agreement (DSC range, 0.57-0.65), with concordance correlation coefficient 0.93 for tumor volume. These findings support anatomically constrained, task-specific segmentation as a reproducible geometric substrate for volumetric tumor-burden quantification, treatment-response assessment, and multimodal outcomes modeling, pending prospective validation in clinical-trial workflows."

Journal • Oncology • Pancreatic Cancer • Solid Tumor

CLINICAL FEATURES, TREATMENTS AND OUTCOME OF PLASMABLASTIC LYMPHOMA: RESULTS FROM A PRELIMINARY ANALYSIS OF THE RETROSPECTIVE INTERNATIONAL PLALY STUDY ON BEHALF OF FIL, LEO/MER REGISTRY AND PLRG (EHA 2026) - "20% patients received bortezomib in association to chemotherapy, 20% radiotherapy (RT) and 14% high dose-chemotherapy (HD-CT) and/or autologous stem cell transplantation (ASCT) consolidation...Twenty-one deaths occurred: 71% due to disease progression. Summary/Conclusion In this preliminary analysis new risk factors, such as ECOG PS >1, >1 extranodal site and diagnosis before 2015, have been identified; patients treated with upfront consolidation therapy tend to have better survival, which needs to be confirmed in the whole cohort we expected to enroll in the study."

Retrospective data • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • CD4

MANAGEMENT AND OUTCOME OF SECONDARY CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN AN INTERNATIONAL COHORT OF 62 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) (EHA 2026) - P | "The 30 pts with PD received brain irradiation-based therapy (n=12), ITC (n=3), high-dose ifosfamide/cytarabine-based chemo (n=8), checkpoint inhibitors (n=2), or BSC (n=5); 13 (9 after brain irradiation, 3 after ITC, 1 after chemo) achieved CR and proceeded with CAR-T (n=8), ASCT (n=4), or ibrutinib (n=1); all remain alive and disease-free at 10-132 months (median 45)...CAR-T, preceded by brain irradiation or ITC as bridging, provides long-term disease control even in HD-MTX-refractory pts. In contrast, late CNS involvement in multiply relapsed PMLBCL has a dismal prognosis."

Clinical • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma

HEPEPO: Effects of Intravenous Injection of Erythropoietin on Hepcidin Pharmacokinetics in Healthy Volunteers (clinicaltrials.gov) - P=N/A | N=14 | Completed | Sponsor: Rennes University Hospital | Unknown status ➔ Completed

Trial completion • Metabolic Disorders

Electrode-omics reveals epochs in silicon anode evolution underpinning electrochemomechanical resilience. (PubMed, Sci Adv) - "This identifies reactions rooted in "SuFEx" chemistry, where oxoanionic LiO-R and Li2O species, electrochemically generated in the solid-electrolyte interphase, chemically react with FSI- in the electrolyte to form emergent species. This sequence of evolutionary bursts produces a mechanically resilient composite that reduces silicon anode cracking over hundreds of cycles, leading to overpotential increase of only ~0.01 volts after 200 cycles."

Journal

CRISPR/Cas‑driven biosensing: molecular mechanisms and advances in diagnostics. (PubMed, Mol Biol Rep) - "Finally, we emphasize the clinical relevance, scalability challenges, and translational potential of these platforms, providing insights into their application in early disease diagnosis, real-time monitoring, and point-of-care testing. Overall, this review offers a critical perspective on current limitations and future directions, positioning CRISPR-based biosensors as promising tools for next-generation precision diagnostics and improved global health outcomes."

Journal • Review

Contextual gating of whisker-evoked responses by frontal cortex supports flexible decision making. (PubMed, Nat Commun) - "Notably, we found that context and whisker sensory processing appeared to be integrated first in wM2, whose activity predicted future lick initiation in both correct hit trials and false alarm error trials already within 30 ms after whisker deflection. We thus identify wM2 as a key node for the contextual gating of the transformation of whisker sensation into motor commands for goal-directed licking."

Journal

Risk factors for postoperative cerebrospinal fluid leak following endoscopic transsphenoidal surgery for craniopharyngioma: a multicenter cohort study with a contemporary surgeon practice survey. (PubMed, J Neurooncol) - "Postoperative CSF leak in Craniopharyngioma has evolved. The study highlights a significant divergence between expert perception and clinical data regarding lumbar drains."

Journal • Retrospective data • Brain Cancer • CNS Tumor • Oncology

Standardizing Stimulus Parameters for Noisy Galvanic Vestibular Stimulation. (PubMed, J Audiol Otol) - "Reports should specify the electrode polarity, passband and filter details, amplitude reference (peak, peak-to-peak, or root-mean-square), threshold procedures, and total stimulation dose...Priorities for future research include head-to-head tests of montage and frequency, individualized dose-response and after-effect mapping, stratification by baseline vestibular status, and mechanistic biomarkers tied to behavior. Standardized parameters and reporting will enable robust meta-analyses and faster clinical translation."

Journal • Review • CNS Disorders

Biomarkers. (PubMed, Alzheimers Dement) - "Automated CT brain segmentation guided by MRI-derived labels demonstrates clinically acceptable segmentation performance on untrained dementia cohort. nnU-Net is more resource-efficient and suitable for limited-resource settings, while MedNeXt has higher accuracy excelling in multi-orientation and multi-modal datasets. These findings validate the feasibility of using CT imaging with advanced segmentation frameworks to develop accessible neuroimaging tools for Alzheimer's and dementia research, addressing diagnostic challenges across diverse clinical contexts."

Biomarker • Journal • Alzheimer's Disease • CNS Disorders • Dementia

Biomarkers. (PubMed, Alzheimers Dement) - "Plasma biomarkers of AD pathology, neuronal injury, and astrogliosis, measured at different life epochs (midlife vs. late-life) show distinct association patterns with subsequent changes in cognitive function across domains."

Biomarker • Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • APOE • Aβ42 • GFAP • p-tau181